DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
PARSIFAL
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
BREAST
(Journal) The Oncologist
2023
BIOPER
Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
BREAST
(Journal) Clinical Cancer Research
2023
PARSIFAL
ctDNA-based DNADX in hormone receptor-positive and HER2-negative (HR+/HER2-) advanced breast cancer following
endocrine therapy and CDK4/6 inhibition: a correlative analysis from the randomized phase 2 PARSIFAL trial
BREAST
SABCS
2023
DEBBRAH
Trastuzumab Deruxtecan in patients with HER2[+] or HER2-Low
Advanced Breast Cancer and Pathologically Confirmed
Leptomeningeal Carcinomatosis: Results from Cohort 5 of the
DEBBRAH Study
BREAST
SABCS
2023
LUPER
en proceso
LUNG
ESMO
2023
PALMIRA
Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
BREAST
ASCO
2023
ATRACTIB
Efficacy and safety of first-line atezolizumab + bevacizumab +
paclitaxel in patients with advanced triple-negative breast cancer:
the ATRACTIB phase 2 trial
BREAST
SABCS
2023
OTHER
A single-arm study design with non-inferiority and superiority time-to-event endpoints: a tool for proof-of-concept and de-intensification strategies in breast cancer
BREAST
(Journal) Frontiers in Oncology
2023
PRIMED
A phase 2 trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED Study
BREAST
ESMO Breast
2023
PHERGAIN (sub-study)
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response (pCR) in HER2-positive early breast cancer (EBC): An exploratory analysis of the PHERGain trial
BREAST
ESMO
2023
PARSIFAL
PARSIFAL-LONG: Extended follow-up of hormone receptorpositive/HER2-negative advanced breast cancer patients treated
with fulvestrant and palbociclib vs letrozole and palbociclib in the
PARSIFAL study
BREAST
SABCS
2023
DEBBRAH
Trastuzumab Deruxtecan in Patients with Unstable Central Nervous System Involvement from HER2-low advanced Breast Cancer: The DEBBRAH Trial
BREAST
SABCS
2022
Other MEDSIR related articles
